Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference
Boehringer Ingelheim Pharmaceuticals has announced that 29 abstracts from the company's respiratory portfolio will be presented at the 2015 American Thoracic Society (ATS) International Conference taking place 15–20 May in Denver, including data on investigational therapies for chronic obstructive pulmonary disease (COPD) and asthma, and on approved products for idiopathic pulmonary fibrosis (IPF) and COPD. Of the 29 accepted abstracts, 19 are on COPD, including key data from the Phase III TONADO trials of late-stage, investigational tiotropium/olodaterol Respimat.
"We are proud of our long-standing commitment to ongoing innovation in discovering and developing new treatments for serious lung conditions where there is an unmet need," said Danny McBryan, vice president, Clinical Development and Medical Affairs, Respiratory, Boehringer Ingelheim Pharmaceuticals, Inc. "We look forward to sharing our asthma, IPF and late-stage COPD data at ATS, as we continue to advance our portfolio of respiratory products."
In addition to the data presentations, Boehringer Ingelheim will provide attending healthcare professionals with several educational opportunities, including an Industry Theater Presentation, "The Role of Bronchodilators in the Long-Term Maintenance Treatment of Patients with COPD: A Review of the Data" (18 May at 11:45 am MT), and a dinner symposium featuring a panel of experts, "Selection of Long-Term Maintenance Therapy for Patients With COPD" (19 May at 6:30 pm MT).
Chronic Obstructive Pulmonary Disease (COPD) Presentations
Sub-analyses from the TONADO trials investigating the safety and efficacy of tiotropium/olodaterol Respimat in patients with COPD will be presented.
Tiotropium/olodaterol Respimat is an investigational maintenance treatment for patients with COPD and includes tiotropium, the active ingredient in Spiriva Respimat (tiotropium bromide) Inhalation Spray and Spiriva HandiHaler (tiotropium bromide inhalation powder), combined with olodaterol. Tiotropium/olodaterol Respimat is not currently approved and its efficacy and safety is being evaluated. Additional analyses will also be presented from the ANHELTO studies of Spiriva HandiHaler and olodaterol Respimat versus Spiriva HandiHaler alone, as well as the WISDOM trial evaluating the stepwise withdrawal of inhaled corticosteroids (ICS) in COPD. Also being presented are further analyses from the TIOSPIR trial comparing Spiriva Respimat and Spiriva HandiHaler.
Related News
-
News CPHI Podcast Series: The power of proteins in antibody drug development
In the latest episode of the CPHI Podcast Series, Lucy Chard is joined by Thomas Cornell from Abzena to discuss protein engineering for drug design and development. -
News Amgen sues Samsung biologics unit over biosimilar for bone disease
Samsung Bioepis, the biologics unit of Samsung, has been issued a lawsuit brought forth by Amgen over proposed biosimilars of Amgen’s bone drugs Prolia and Xgeva. -
News CPHI Podcast Series: Why we need to consider women in clinical trials
The latest episode of the CPHI Podcast Series with Lucy Chard covers women's health, specifically women's representation in clinical trials, the associated bias, and the impacts on health for this population. -
News US FDA does not approve MDMA therapy for PTSD, requests more data
The MDMA-based therapeutic developed by Lykos Therapeutics, a California-based Public Benefit Corporation (PBC), has been reviewed and unapproved by the US FDA. The regulator has requested additional phase III trial data for further safety and efficacy... -
News Novartis and Viatris latest facing lawsuit over HeLa cell misuse
Global pharmaceutical companies Novartis and Viatris are the latest hit with a lawsuit claim pertaining to alleged misuse of the ‘HeLa’ cell line from the estate of woman whose cancerous tissue cells were taken without consent. -
News Sanofi invests billions into Frankfurt insulin production site
French pharmaceutical company Sanofi have announced an investment of EUR1.3 billion at their existing BioCampus site in Frankfurt am Main for the expansion of insulin production. -
News Novel oral Type 1 diabetes drug gains US FDA IND designation
A University of Alabama at Birmingham startup has gained FDA clearance for Investigational New Drug clinical trials for an oral Type 1 diabetes drug, a milestone for diabetes treatment. -
News A Day in the Life of a Vice President in R&D & Engineering
In the Day in the Life of Series, we've already had the chance to get to know a range of people in various roles in the pharma industry. In the latest interview we get a glimpse into the R&D side of things from Jennifer Sorrells, Vice Presiden...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance